Comprehensive genomic profiling (CGP) is a transformative approach to inform oncology decisions. Numerous cancer biomarkers are assessed simultaneously to identify patient-specific treatment options, risk factors, and clinical trial eligibility. A pivotal step in CGP is mapping the tumor or germline profile of a cancer patient against the world’s biomedical knowledge. The sheer volume and complexity of relevant data makes this process challenging.

MH Guide is a tertiary analysis solution that automates the annotation of genetic variants to accurately interpret CGP results and hereditary cancer analyses. Evidence-based therapy options are clearly laid out, so treatment for every case is based on optimally informed decision support.